Lonza AG

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We focus on enabling treatments that prevent illness and support healthier lifestyles. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.

News from this company


Lonza Announces New Mid-Term Guidance 2024 – 2028

17.10.2023 -

At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.


Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

06.10.2023 -

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner...


Lonza-CEO Ruffieux to Leave Swiss CDMO

18.09.2023 -

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September.

Chemistry & Life Sciences

Integrated Drug Development Models

13.05.2022 -

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.


Lonza Specialty Ingredients to be sold to Bain Capital and Cinven

09.02.2021 -

Lonza has signed a definitive agreement to divest its Specialty Ingredients business to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion.

Chemistry & Life Sciences

The Rise of HPAPI Molecules

10.09.2020 -

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.


Lonza’s Corporate Overhaul

28.10.2013 - Strategic Maneuvers - When Richard Ridinger took over as CEO of Basel, Switzerland-based Lonza in May 2012, the 115-year old life science and chemical company with sales of just...


Lonza To Build Formulation Plant in Visp

10.08.2011 - Lonza said it will be investing CHF 5.8 million in a formulation plant for its Meta metaldehyde in Visp, Switzerland. The company said the plant will enable it to supply its own...


Lonza to Buy Arch Chemicals for $1.2 Billion

12.07.2011 - Lonza said it will acquire U.S. biocide producer Arch Chemicals for about $1.2 billion. The cash offer is subject to customary conditions including the tendering of more than two...


Lonza Expects Solid Growth in 2011, 2010 Net Up 79%

27.01.2011 - Swiss drugs industry supplier Lonza said on Wednesday it expects solid growth in 2011 after meeting forecasts with a 79 percent rise in full-year net profit. Net profit at the...


Lonza Shares Fall After Deutsche Bank Downgrade

11.01.2011 - Shares in Swiss drugs industry supplier Lonza fell over 4% on Monday after Deutsche Bank analysts downgraded the stock as they expect the strong Swiss franc and a tougher...


Stefan Borgas: Strong Franc Major Challenge for Swiss Economy

10.01.2011 - The strong Swiss franc will be a major challenge for the Swiss economy in the next five years, Lonza Chief Executive Stefan Borgas was quoted as saying in a newspaper interview on...


H1 2010: Lonza Reports Improved Order Placement and Contract Signing

22.07.2010 - Lonza has announced sales of CHF 1,301 million for H1 2010, which was similar level to H1 2009 (-2.1%). The company said this was due to an expectedly weak first quarter in custom...

Sites & Services

Adapting For Survival

26.01.2010 - The Chinese chemical and pharmaceutical industry has established itself as a significant player in the world. The number of chemical and pharmaceutical companies is continuously...

Products from this company

Research / Laboratory

Successful Clinical to Commercial Bioconjugate Manufacturing

Lonza AG -

Ever since antibody drug conjugates (ADCs) were first reported in the 1970s, the field of bioconjugation has found itself in a constant state of evolution.

Research / Laboratory

Improving ADC Production and Purification

Lonza AG -

How Optimizing Process Parameters Can Improve Scalability and Manufacturability of a Cytotoxic Antibody Drug Conjugate.

Pharma- & Biotech Processing

Lonza Launches PBPK Modelling Service to de-risk Drug Development

Lonza AG -

The new PBPK modelling service from Lonza combines computer models with experiments to predict a molecule’s PK, and whether solubility problems might need solving.


Lonza AG

Muenchensteinerstrasse 38
4002 Basel